This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $300 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoLive In-Person Event: December 4 - 8, 2022

Rajkumar Ganesan, PhD
Executive Director, Oncology Research at Amgen


Currently, an Executive Director at Amgen and oversee preclinical discovery efforts for immunotherapeutics. I received my PhD in Molecular Biology / Biochemistry from University of Zurich. Over the last 15+ years, while working for Genentech, AstraZeneca, Boehringer Ingelheim, Janssen, my team and I led the discovery efforts for molecular and cellular therapies and progressed series of Biotherapeutics and CAR-Ts for clinical development. Notable accomplishments include discovery of SPEVIGO® (Spesolimab) and pre-clinical discovery of multiple T cell engagers for hematological malignancies and solid tumors. I’m passionate about the emerging approaches for the design and development of next-generation T cell engagers.

Agenda Sessions

  • AMG 509, A STEAP1-Targeted Bispecific Immune Therapy for the Treatment of Prostate Cancer and Ewing Sarcoma